124730-56-9

Basic information

• Product Name: 4H-PYRROLO[3,2,1-IJ]QUINOLINE-1-CARBOXYLIC ACID,5,6-DIHYDRO-
• Synonyms: 4H-PYRROLO[3,2,1-IJ]QUINOLINE-1-CARBOXYLIC ACID,5,6-DIHYDRO-;5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-carboxylic acid;2,3-Dihydro-1H-pyrrolo[3,2,1-ij]quinoline-6-carboxylic acid;4H-PYRROLO[3,2,1-IIJ]QUINOLINE-1-CARBOXYLIC ACID,5,6-DIHYDRO-
• CAS NO: 124730-56-9
• Molecular Formula: C₁₂H₁₁NO₂
• Molecular Weight: 201.23
• Mol File: 124730-56-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 460.523°C at 760 mmHg
• Flash Point: 232.316°C
• Appearance: /
• Density: 1.38
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.693
• CAS DataBase Reference: 4H-PYRROLO[3,2,1-IJ]QUINOLINE-1-CARBOXYLIC ACID,5,6-DIHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-PYRROLO[3,2,1-IJ]QUINOLINE-1-CARBOXYLIC ACID,5,6-DIHYDRO-(124730-56-9)
• EPA Substance Registry System: 4H-PYRROLO[3,2,1-IJ]QUINOLINE-1-CARBOXYLIC ACID,5,6-DIHYDRO-(124730-56-9)

Safety Data

• Hazardous Substances Data: 124730-56-9(Hazardous Substances Data)

Usage

General Description

4H-PYRROLO[3,2,1-IJ]QUINOLINE-1-CARBOXYLIC ACID,5,6-DIHYDRO- is a chemical compound with a complex structure and a carboxylic acid group. It is a heterocyclic compound with a quinoline core, and the presence of a carboxylic acid group makes it a versatile building block for the synthesis of various pharmaceuticals and organic compounds. The 5,6-dihydro- substitution in the compound indicates the presence of hydrogen atoms at the 5th and 6th positions of the quinoline ring, which can affect its reactivity and biological activity. 4H-PYRROLO[3,2,1-IJ]QUINOLINE-1-CARBOXYLIC ACID,5,6-DIHYDRO- has potential applications in medicinal chemistry and drug discovery due to its unique structure and potential pharmacological properties.

InChI:InChI=1/C12H11NO2/c14-12(15)10-7-13-6-2-4-8-3-1-5-9(10)11(8)13/h1,3,5,7H,2,4,6H2,(H,14,15)

Upstream product

• 124730-53-6 5,6-dihydro-4H-pyrrolo [3,2,1-ij]quinoline-1-carboxylic acid ethyl ester 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 152712-44-2 3-(3,4-dihydro-2H-quinolin-1-yl)-2-oxopropionic acid ethyl ester 

Downstream Products

• 5840-01-7 5,6-dihydro-4H-pyrrolo-[3,2,1-ij]quinoline 
• 1122597-41-4 methyl 4-{[(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-ylcarbonyl)amino]methyl}benzoate 
• 905854-16-2 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(2-chloro-4-fluorophenyl)pyrrole-2,5-dione 
• 1000873-98-2 3(S),4(R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 1000873-98-2 tivatinib 
• 905854-03-7 (+)-3(S),4(S)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-j]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 905854-02-6 Tivantinib 
• 345264-02-0 (5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)oxoacetic acid methyl ester 
• 345261-20-3 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dion 
• 1000873-98-2 (±)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 1000873-98-2 (±)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 905854-06-0 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(3-methoxyphenyl)pyrrole-2,5-dione 

Relevant articles and documents

COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

PURINE DERIVATIVES AS KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.

Development of high-affinity 5-HT3 receptor antagonists. Structure- affinity relationships of novel 1,7-annelated indole derivatives. 1

On the basis of the structures of ondansetron and GR 65,630, its ring- opened C-linked methylimidazole analogue, novel 1,7-annelated indole derivatives were synthesized as potential 5-HT3 antagonists. Receptor binding studies show that all compounds display a high affinity for the 5- HT3 receptors. In both series annelation results in compounds being 7 and 4 times more potent than the references ondansetron and GR 65,630, respectively. Similar to ondansetron, the 1,7-annelated indoles show little stereoselectivity. The (-)-isomers are only slightly more potent than the (+)-isomers. The receptor binding profile of l-10-[(2-methyl-1H-imidazol-1- yl)methyl]-5,6,8,9,10,11-hexahydro-4H-pyrido[3,2,1-jk]carbazol-11-one hydrochloride (24b) (INN cilansetron) shows that the compound displays, besides a high affinity for 5-HT3 receptors (K(i) = 0.19 nM), a weak affinity for σ-receptors (K(i) = 340 nM), muscarine M1 receptors (K(i) = 910 nM), and 5-HT4 receptors (K(i) = 960 nM) and no affinity (K(i) ≥ 5000 nM) for all the other receptor types tested (n = 37). The new compounds fit the proposed necessary chemical template for binding: a heteroaromatic ring system, a coplanar carbonyl group, and a nitrogen center at well-defined distances. The enhanced potency of the annelated 1,7-indole derivatives indicates that the extra ring provides a favorable hydrophobic area for interaction with the 5-HT3 receptor site. In vivo cilansetron is more potent and induces less central side effects than ondansetron. At present cilansetron is in clinical trials.